AVIcure Bioscience develops and markets patented medical devices using ultraviolet light technology. It has 8 employees and is located in Bethlehem, PA. It focuses on blood pathogen reduction, immune system stimulation, and pain relief. Its products include the HemaSterilizer blood pathogen reduction device, ImmunoModulator for immune system stimulation, and AVIcure device for pain relief. It has a strong IP position and management team with expertise in science and business.
AVIcure Bioscience is seeking $20 million in funding to conduct clinical trials for their flagship medical device, the ImmunoModulatorTM. The device uses ultraviolet blood irradiation (UVBI) technology to treat blood-borne diseases like Crohn's Disease. UVBI has been shown to inactivate pathogens by preventing their replication through molecular damage to DNA/RNA. The chair and co-founder, Dr. Kuenstner, developed the device to find a cure for Crohn's Disease after family members suffered from it. The ImmunoModulatorTM was designed over 5 years incorporating patented engineering innovations to safely and effectively treat blood outside the body using optimized UV wavelengths. Previous studies indicate the device mitigates symptoms
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
The first section of Part III will cover the most immediate healthcare response - which is to test and diagnose patients for COVID-19, to get a clear picture on the extent of the spread of infection. It also covers the current technologies used in diagnostics: RT-PCR, LAMP, Lateral Flow and ELISA. It would also highlight key companies and comparison of the technologies involved.
In this section of the coronavirus pandemic series, we discuss the current capacity of local healthcare systems and the need for effective treatment options as well as the pathogenesis of the coronavirus. Current treatment options include RNA, monoclonal antibodies (mAb), antibodies, convalescent plasma, and others. Critical stage implications such as cytokine storm and the need for immunomodulatory agents would also be discussed. Therapeutic pathways would are also compared.
COVID-19; Updates on Pathophysiology and Laboratory InvestigationsAbdulsalam Al-Ani
This document discusses the pathophysiology and laboratory investigations of COVID-19. It begins with an overview of the objectives and then discusses the direct viral infection process, the immune response, and COVID-19 induced coagulopathy as they relate to the pathophysiology. It also discusses several diagnostic and prognostic laboratory parameters including viral detection methods, antibody detection, and hematological parameters seen in complete blood counts. Specifically, it notes the role of hypoxia-inducible factors, inflammation, and endothelial injury in driving the coagulopathy seen in COVID-19 patients.
The document outlines South Africa's strategy for rolling out Covid-19 vaccines. It establishes a Ministerial Advisory Committee on vaccines to provide advice on vaccine options, purchasing, priority groups, and rollout strategy. It proposes a phased rollout approach prioritizing healthcare workers, essential workers, elderly, and those with comorbidities. The strategy considers vaccine selection criteria like availability, efficacy, storage requirements, and cost. It also addresses regulatory approvals, procurement, distribution, data collection, and negotiations with vaccine manufacturers.
This was a lecture I gave for the Upstate Nurse Practitioners Association. This is a comprehensive overview. I would to thank all health care professionals for doing their jobs as well as they can.
AVIcure Bioscience is seeking $20 million in funding to conduct clinical trials for their flagship medical device, the ImmunoModulatorTM. The device uses ultraviolet blood irradiation (UVBI) technology to treat blood-borne diseases like Crohn's Disease. UVBI has been shown to inactivate pathogens by preventing their replication through molecular damage to DNA/RNA. The chair and co-founder, Dr. Kuenstner, developed the device to find a cure for Crohn's Disease after family members suffered from it. The ImmunoModulatorTM was designed over 5 years incorporating patented engineering innovations to safely and effectively treat blood outside the body using optimized UV wavelengths. Previous studies indicate the device mitigates symptoms
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
The first section of Part III will cover the most immediate healthcare response - which is to test and diagnose patients for COVID-19, to get a clear picture on the extent of the spread of infection. It also covers the current technologies used in diagnostics: RT-PCR, LAMP, Lateral Flow and ELISA. It would also highlight key companies and comparison of the technologies involved.
In this section of the coronavirus pandemic series, we discuss the current capacity of local healthcare systems and the need for effective treatment options as well as the pathogenesis of the coronavirus. Current treatment options include RNA, monoclonal antibodies (mAb), antibodies, convalescent plasma, and others. Critical stage implications such as cytokine storm and the need for immunomodulatory agents would also be discussed. Therapeutic pathways would are also compared.
COVID-19; Updates on Pathophysiology and Laboratory InvestigationsAbdulsalam Al-Ani
This document discusses the pathophysiology and laboratory investigations of COVID-19. It begins with an overview of the objectives and then discusses the direct viral infection process, the immune response, and COVID-19 induced coagulopathy as they relate to the pathophysiology. It also discusses several diagnostic and prognostic laboratory parameters including viral detection methods, antibody detection, and hematological parameters seen in complete blood counts. Specifically, it notes the role of hypoxia-inducible factors, inflammation, and endothelial injury in driving the coagulopathy seen in COVID-19 patients.
The document outlines South Africa's strategy for rolling out Covid-19 vaccines. It establishes a Ministerial Advisory Committee on vaccines to provide advice on vaccine options, purchasing, priority groups, and rollout strategy. It proposes a phased rollout approach prioritizing healthcare workers, essential workers, elderly, and those with comorbidities. The strategy considers vaccine selection criteria like availability, efficacy, storage requirements, and cost. It also addresses regulatory approvals, procurement, distribution, data collection, and negotiations with vaccine manufacturers.
This was a lecture I gave for the Upstate Nurse Practitioners Association. This is a comprehensive overview. I would to thank all health care professionals for doing their jobs as well as they can.
Ribomed Biotechnologies has been selected as the prime contractor on a $3.5 million contract from the Department of Homeland Security to develop a device to test food for biological threats. The company is also working on contracts with DARPA to develop portable sensors to detect biological agents. Additionally, Ribomed is exploring opportunities in medical diagnostics, including early cancer detection by identifying cancer-related genes. The company's president has also established an incubator space for three startup biotech firms.
Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&DInsideScientific
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.
LIDE’s novel MiniPDX is a 7-day, in vivo drug efficacy test for oncology therapeutics. It is the in vivo version of a 3D organoid assay and correlates with traditional PDX by 92%, and with clinical end point at 82%. These high correlations make MiniPDX an effective option to test targeted drugs, chemotherapies, angiogenesis drugs, and more, while demonstrating superior testing times and cost-effectiveness versus traditional PDX. In a clinical setting, MiniPDX, together with next-generation sequencing (NGS), is playing an emerging role in personalized oncology.
The process starts with a freshly prepared cell suspension from either a clinical sample or PDX (Patient Derived Xenograft) model. This sample is sealed into a mini capsule with 500 KD cut-off pores. Capsules are implanted into SCID mice subcutaneously, and a test compound is given systemically for 7 days. The efficacy of the test compound is then evaluated by measuring ATP of the cancer cells in the capsule.
The MiniPDX mouse trial can also be coupled with “K-Cell Omic” analysis (DNA, RNA, and Protein), presenting a powerful tool for the identification of drug candidates and the discovery of companion diagnostic markers.
Key Topics Include:
Understand how MiniPDX + Omics analysis empowers precision medicine
Pros and cons of functional diagnosis assays (CR, Organoid, MiniPDX, PDX)
How to leverage MiniPDX + Omics for the identification of drug candidates
Role of K Cell RNAseq + FGI (Functional Genomic Imaging)
LIDE’s PMed Trial database for AI aided drug discovery
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Benitec Biopharma 'Gene Silencing for Life' including 'ddRNAi: A quiet revolution in therapeutics'
Presented by Bob Atwill, Senior Vice President of New Business & Collaborations
Presented at the Fortune Forum 2015 Australian Summit
This document discusses developing a new antiviral drug to treat COVID-19. It notes that current treatments are not fully effective and an oral drug is needed that can cure early infections. The company, AntiRNA, plans to develop drugs that interfere with viral RNA methylation, an approach they have previously used successfully against other viruses. Their proposed approach involves first synthesizing and testing prototype drugs in vitro and in vivo in Phase 1, then synthesizing derivatives and testing them in Phase 2. If successful, the potential market could be in billions annually given the lack of existing treatments. The company founders have extensive experience in antiviral drug development.
SARS-CoV-2 is a novel coronavirus that causes COVID-19. It is believed to have originated in bats and potentially spread to humans through an intermediate host. The virus uses the ACE2 receptor to enter human cells. Early studies found COVID-19 has an R0 value similar to SARS and pandemic flu. Symptoms include fever, cough, fatigue and shortness of breath. Chest CT often shows bilateral lung infiltrates. Treatment focuses on supportive care while research investigates antivirals like remdesivir and chloroquine. Prevention strategies aim to slow the spread through social distancing, quarantines and hygiene practices.
Constance Benson, MD
Professor of Medicine and Director of the UC San Diego
AntiViral Research Center
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
The outbreak of Covid 19 was initially identified in Wuhan city of China in December 2019 and led to a global pandemic. Clinical evidence indicates that covid 19 infection can range from asymptomatic or mild symptoms in the majority of cases to serious complication such as ARDS, multi organ failure and death in severe cases. It has been also indicated that there is uncontrolled and excessive production of cytokine in critically ill patients of covid 19 which give rise to “cytokine storm”. Which are responsible for the exacerbation of symptoms and development of the disease There are many unresolved questions regarding the pathological features, pathophysiological mechanisms and treatment of the cytokine storm induced by covid 19. This review will be aimed at suggesting therapeutic strategies such as the use of immunomodulators to confront the cytokine storm and an overview of the current understanding of the covid 19 infection. Shatabdi Dey | Sreekiran. CV "Cytokine and COVID19: A Literature Review" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-6 , October 2020, URL: https://www.ijtsrd.com/papers/ijtsrd33685.pdf Paper Url: https://www.ijtsrd.com/biological-science/immunobiology/33685/cytokine-and-covid19-a-literature-review/shatabdi-dey
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. The fact that the transplantation of MSCs improved the outcome of COVID-2019 patients may be due to regulating inflammatory response and promoting tissue repair and regeneration. This is a preliminary report of our study in Iran.
Cytokine storm in COVID-19 PATIENTS is characterised by fever, cough and acute respiratory distress. The mortality rate of COVID-19 patients who were mechanically ventilated in 7 studies is about 60%...Laboratory studies showed that these patients had clinical features suggestive of hypercytokinemia and hyperinflammation associated with multi-organ failure
- GeoVax Labs is developing both preventative and therapeutic HIV/AIDS vaccines using DNA and MVA technologies exclusively licensed from Emory University.
- Their preventative vaccine has completed a Phase 2a trial and plans to begin a Phase 2b efficacy trial in 2013. Their therapeutic vaccine is currently enrolling patients in a Phase 1/2 trial.
- Both vaccines have shown compelling results in pre-clinical studies, inducing antibody and T-cell immune responses against HIV.
The document summarizes information about various COVID-19 vaccines that have been approved or are in clinical trials globally. It provides details on the efficacy, dosing, storage and distribution of the Pfizer, Moderna, and Oxford/AstraZeneca vaccines. It also discusses Bangladesh's plans to obtain the Oxford/AstraZeneca vaccine in January 2021, as it can be stored at higher temperatures than the mRNA vaccines and will allow the country to vaccinate 1.5 crore people.
1. Genome of corona viruses
2. Comparative analysis of emergence and spreading
3. Entry Mechanism
4. COVID-19 Case Study
5. Face mask Case Study
6. Pharmacologic Treatments for Coronavirus Disease
7. BCG vaccine
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Know your COVID-19 Vaccine (Philippines)AxcelPerez1
The content aims to contribute spreading right information about COVID-19 Vaccine. The information are from World Health Organization and Philippine Department of Health. This may help my fellow Filipino to build his/her confidence to get vaccinated.
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...Guy Boulianne
This document discusses the potential use of vaccines and genetic engineering techniques to develop biological weapons. It describes how vaccines could be used to weaken a population's immunity before a secondary biological attack. It also outlines how genetic engineering of pathogens could make them more resistant, toxic, stable and virulent. Projects from Soviet-era bioweapons programs, like Obolensk and Vector, are cited as pursuing techniques like modifying viruses with toxin genes or creating antibiotic-resistant strains. The goals of such research are said to include increasing a pathogen's pathogenicity and creating novel strains with new dangerous properties.
This document provides information about COVID-19 (coronavirus disease). It discusses the symptoms, transmission, diagnosis and treatment of the disease. The diagnosis sections describe molecular diagnosis using RT-PCR testing of genes like ORF1ab and N, as well as antibody testing methods like ELISA and rapid lateral flow tests. Inflammatory markers associated with COVID-19 are also summarized, including increased levels of cytokines, C-reactive protein, erythrocyte sedimentation rate and liver enzymes. Potential treatments mentioned include antiviral drugs, corticosteroids, remdesivir and chloroquine.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
This document summarizes Inovio Pharmaceuticals' DNA vaccine platform and clinical programs. It discusses how Inovio is revolutionizing vaccines by developing DNA vaccines that generate robust immune responses against diseases like cancer, HIV, influenza, and hepatitis C. Inovio has multiple vaccines in Phase I and II clinical trials showing favorable safety profiles and strong immune responses. The company is working to further validate its platform through additional clinical trial results and partnerships with larger pharmaceutical companies.
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...Golden Helix
Comprehensive genomic testing via next generation sequencing (NGS) is being increasingly adapted as part of cancer care in conjunction with molecular and immunohistochemical tests. Comprehensive genomic profiling potentially expands the number of targeted therapies that are available to patients, improves patient diagnosis and prognosis, and increases the number of clinical trials that are relevant to patients. However, with these advancements come challenges such as gaps in expertise resulting in inadequate efforts to interpret genomic data accurately and efficiently, poorly coordinated efforts to implement precision care, patients being diagnosed and treated despite inadequate access to relevant information and subsequent lack of patient exposure to all available treatment options.
Golden Helix CancerKB v2.0 provides a means of closing the gap, whether you're a beginner who is trying to capture the vast amount of knowledge in the cancer field or an expert who has high sample volume AND needs to keep up with the ever-evolving knowledge of Tier II and III variants. In this webcast, we will discuss and apply Golden Helix CancerKB in the context of cancer precision medicine. Golden Helix CancerKB is systematically curated and reviewed by experts in the field and contains information about cancer genes, biomarkers, and treatments generated from several trusted cancer resources. With VarSeq 2.3.0’s added support for comprehensive cancer genomic profiling tests, Golden Helix CancerKB has expanded to include interpretations for genomic signatures, combination biomarkers, and more investigational (tier II) biomarkers, among several other additions that will be discussed. With the Golden Helix CancerKB database, users will experience a streamlined automatic matching of biomarkers to available drugs and trials which ultimately saves users massive amounts of time and effort while reducing the possibility for errors.
Ribomed Biotechnologies has been selected as the prime contractor on a $3.5 million contract from the Department of Homeland Security to develop a device to test food for biological threats. The company is also working on contracts with DARPA to develop portable sensors to detect biological agents. Additionally, Ribomed is exploring opportunities in medical diagnostics, including early cancer detection by identifying cancer-related genes. The company's president has also established an incubator space for three startup biotech firms.
Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&DInsideScientific
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.
LIDE’s novel MiniPDX is a 7-day, in vivo drug efficacy test for oncology therapeutics. It is the in vivo version of a 3D organoid assay and correlates with traditional PDX by 92%, and with clinical end point at 82%. These high correlations make MiniPDX an effective option to test targeted drugs, chemotherapies, angiogenesis drugs, and more, while demonstrating superior testing times and cost-effectiveness versus traditional PDX. In a clinical setting, MiniPDX, together with next-generation sequencing (NGS), is playing an emerging role in personalized oncology.
The process starts with a freshly prepared cell suspension from either a clinical sample or PDX (Patient Derived Xenograft) model. This sample is sealed into a mini capsule with 500 KD cut-off pores. Capsules are implanted into SCID mice subcutaneously, and a test compound is given systemically for 7 days. The efficacy of the test compound is then evaluated by measuring ATP of the cancer cells in the capsule.
The MiniPDX mouse trial can also be coupled with “K-Cell Omic” analysis (DNA, RNA, and Protein), presenting a powerful tool for the identification of drug candidates and the discovery of companion diagnostic markers.
Key Topics Include:
Understand how MiniPDX + Omics analysis empowers precision medicine
Pros and cons of functional diagnosis assays (CR, Organoid, MiniPDX, PDX)
How to leverage MiniPDX + Omics for the identification of drug candidates
Role of K Cell RNAseq + FGI (Functional Genomic Imaging)
LIDE’s PMed Trial database for AI aided drug discovery
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Benitec Biopharma 'Gene Silencing for Life' including 'ddRNAi: A quiet revolution in therapeutics'
Presented by Bob Atwill, Senior Vice President of New Business & Collaborations
Presented at the Fortune Forum 2015 Australian Summit
This document discusses developing a new antiviral drug to treat COVID-19. It notes that current treatments are not fully effective and an oral drug is needed that can cure early infections. The company, AntiRNA, plans to develop drugs that interfere with viral RNA methylation, an approach they have previously used successfully against other viruses. Their proposed approach involves first synthesizing and testing prototype drugs in vitro and in vivo in Phase 1, then synthesizing derivatives and testing them in Phase 2. If successful, the potential market could be in billions annually given the lack of existing treatments. The company founders have extensive experience in antiviral drug development.
SARS-CoV-2 is a novel coronavirus that causes COVID-19. It is believed to have originated in bats and potentially spread to humans through an intermediate host. The virus uses the ACE2 receptor to enter human cells. Early studies found COVID-19 has an R0 value similar to SARS and pandemic flu. Symptoms include fever, cough, fatigue and shortness of breath. Chest CT often shows bilateral lung infiltrates. Treatment focuses on supportive care while research investigates antivirals like remdesivir and chloroquine. Prevention strategies aim to slow the spread through social distancing, quarantines and hygiene practices.
Constance Benson, MD
Professor of Medicine and Director of the UC San Diego
AntiViral Research Center
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
The outbreak of Covid 19 was initially identified in Wuhan city of China in December 2019 and led to a global pandemic. Clinical evidence indicates that covid 19 infection can range from asymptomatic or mild symptoms in the majority of cases to serious complication such as ARDS, multi organ failure and death in severe cases. It has been also indicated that there is uncontrolled and excessive production of cytokine in critically ill patients of covid 19 which give rise to “cytokine storm”. Which are responsible for the exacerbation of symptoms and development of the disease There are many unresolved questions regarding the pathological features, pathophysiological mechanisms and treatment of the cytokine storm induced by covid 19. This review will be aimed at suggesting therapeutic strategies such as the use of immunomodulators to confront the cytokine storm and an overview of the current understanding of the covid 19 infection. Shatabdi Dey | Sreekiran. CV "Cytokine and COVID19: A Literature Review" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-6 , October 2020, URL: https://www.ijtsrd.com/papers/ijtsrd33685.pdf Paper Url: https://www.ijtsrd.com/biological-science/immunobiology/33685/cytokine-and-covid19-a-literature-review/shatabdi-dey
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. The fact that the transplantation of MSCs improved the outcome of COVID-2019 patients may be due to regulating inflammatory response and promoting tissue repair and regeneration. This is a preliminary report of our study in Iran.
Cytokine storm in COVID-19 PATIENTS is characterised by fever, cough and acute respiratory distress. The mortality rate of COVID-19 patients who were mechanically ventilated in 7 studies is about 60%...Laboratory studies showed that these patients had clinical features suggestive of hypercytokinemia and hyperinflammation associated with multi-organ failure
- GeoVax Labs is developing both preventative and therapeutic HIV/AIDS vaccines using DNA and MVA technologies exclusively licensed from Emory University.
- Their preventative vaccine has completed a Phase 2a trial and plans to begin a Phase 2b efficacy trial in 2013. Their therapeutic vaccine is currently enrolling patients in a Phase 1/2 trial.
- Both vaccines have shown compelling results in pre-clinical studies, inducing antibody and T-cell immune responses against HIV.
The document summarizes information about various COVID-19 vaccines that have been approved or are in clinical trials globally. It provides details on the efficacy, dosing, storage and distribution of the Pfizer, Moderna, and Oxford/AstraZeneca vaccines. It also discusses Bangladesh's plans to obtain the Oxford/AstraZeneca vaccine in January 2021, as it can be stored at higher temperatures than the mRNA vaccines and will allow the country to vaccinate 1.5 crore people.
1. Genome of corona viruses
2. Comparative analysis of emergence and spreading
3. Entry Mechanism
4. COVID-19 Case Study
5. Face mask Case Study
6. Pharmacologic Treatments for Coronavirus Disease
7. BCG vaccine
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Know your COVID-19 Vaccine (Philippines)AxcelPerez1
The content aims to contribute spreading right information about COVID-19 Vaccine. The information are from World Health Organization and Philippine Department of Health. This may help my fellow Filipino to build his/her confidence to get vaccinated.
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...Guy Boulianne
This document discusses the potential use of vaccines and genetic engineering techniques to develop biological weapons. It describes how vaccines could be used to weaken a population's immunity before a secondary biological attack. It also outlines how genetic engineering of pathogens could make them more resistant, toxic, stable and virulent. Projects from Soviet-era bioweapons programs, like Obolensk and Vector, are cited as pursuing techniques like modifying viruses with toxin genes or creating antibiotic-resistant strains. The goals of such research are said to include increasing a pathogen's pathogenicity and creating novel strains with new dangerous properties.
This document provides information about COVID-19 (coronavirus disease). It discusses the symptoms, transmission, diagnosis and treatment of the disease. The diagnosis sections describe molecular diagnosis using RT-PCR testing of genes like ORF1ab and N, as well as antibody testing methods like ELISA and rapid lateral flow tests. Inflammatory markers associated with COVID-19 are also summarized, including increased levels of cytokines, C-reactive protein, erythrocyte sedimentation rate and liver enzymes. Potential treatments mentioned include antiviral drugs, corticosteroids, remdesivir and chloroquine.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
This document summarizes Inovio Pharmaceuticals' DNA vaccine platform and clinical programs. It discusses how Inovio is revolutionizing vaccines by developing DNA vaccines that generate robust immune responses against diseases like cancer, HIV, influenza, and hepatitis C. Inovio has multiple vaccines in Phase I and II clinical trials showing favorable safety profiles and strong immune responses. The company is working to further validate its platform through additional clinical trial results and partnerships with larger pharmaceutical companies.
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...Golden Helix
Comprehensive genomic testing via next generation sequencing (NGS) is being increasingly adapted as part of cancer care in conjunction with molecular and immunohistochemical tests. Comprehensive genomic profiling potentially expands the number of targeted therapies that are available to patients, improves patient diagnosis and prognosis, and increases the number of clinical trials that are relevant to patients. However, with these advancements come challenges such as gaps in expertise resulting in inadequate efforts to interpret genomic data accurately and efficiently, poorly coordinated efforts to implement precision care, patients being diagnosed and treated despite inadequate access to relevant information and subsequent lack of patient exposure to all available treatment options.
Golden Helix CancerKB v2.0 provides a means of closing the gap, whether you're a beginner who is trying to capture the vast amount of knowledge in the cancer field or an expert who has high sample volume AND needs to keep up with the ever-evolving knowledge of Tier II and III variants. In this webcast, we will discuss and apply Golden Helix CancerKB in the context of cancer precision medicine. Golden Helix CancerKB is systematically curated and reviewed by experts in the field and contains information about cancer genes, biomarkers, and treatments generated from several trusted cancer resources. With VarSeq 2.3.0’s added support for comprehensive cancer genomic profiling tests, Golden Helix CancerKB has expanded to include interpretations for genomic signatures, combination biomarkers, and more investigational (tier II) biomarkers, among several other additions that will be discussed. With the Golden Helix CancerKB database, users will experience a streamlined automatic matching of biomarkers to available drugs and trials which ultimately saves users massive amounts of time and effort while reducing the possibility for errors.
This document summarizes Inovio Pharmaceuticals' DNA vaccine technology and development programs. It discusses Inovio's synthetic DNA vaccines that stimulate both antibody and T-cell immune responses, their electroporation delivery system, and their ability to generate protective responses against multiple unmatched strains of pathogens. The lead program is a therapeutic HPV vaccine in Phase II clinical trials, with efficacy data expected in Q1 2014. Inovio has a pipeline of DNA vaccine programs for cancers and infectious diseases, and pursues partnerships, grants, and clinical trial sponsorships to fund development.
This document provides an overview of Inovio Pharmaceuticals' DNA vaccine technology and development programs. Key points:
- Inovio is developing DNA vaccines that use electroporation to deliver DNA plasmids encoding disease antigens to cells, stimulating antibody and T-cell immune responses.
- Their lead program is a therapeutic HPV vaccine (VGX-3100) in Phase II testing for cervical dysplasia. Efficacy data is expected in mid-2014.
- Inovio's technology is aimed at revolutionizing vaccines by producing ones that are synthetic rather than weakened viruses, can target multiple strains, and stimulate both preventive and therapeutic immune responses.
- They have a pipeline of
This document provides an overview of Inovio Pharmaceuticals' DNA vaccine technology and development programs. Key points:
- Inovio is developing DNA vaccines that use electroporation to deliver DNA plasmids encoding disease antigens to cells, stimulating antibody and T-cell immune responses.
- Their lead program is a therapeutic HPV vaccine (VGX-3100) in Phase II testing for cervical dysplasia. Efficacy data is expected in mid-2014.
- Inovio's technology is aimed at revolutionizing vaccines by producing ones that are synthetic rather than weakened viruses, can target multiple strains, and stimulate both preventive and therapeutic immune responses.
- The company has a pipeline
This document introduces the concept of patient safety and discusses occurrence variance reporting (OVR) and international patient safety goals. It notes that medical errors injure 1 in 25 hospital patients and kill 44,000-98,000 people per year in the US. The goals of patient safety are to detect safety issues, implement preventive actions, and reduce risks. OVR involves voluntary reporting of process variations to improve quality and prevent recurrences. It identifies adverse events, near misses, and sentinel events. The six international patient safety goals focus on correctly identifying patients, improving communication, increasing medication safety, ensuring correct surgical procedures, reducing healthcare-associated infections, and decreasing falls.
PATIENT AND STAFF SAFETY MANAGEMENT.pptxanjalatchi
Patient Safety is a health care discipline that emerged with the evolving complexity in health care systems and the resulting rise of patient harm in health care facilities. It aims to prevent and reduce risks, errors and harm that occur to patients during provision of health care.
PATIENT AND STAFF SAFETY MANAGEMENT.pptxanjalatchi
What is Patient Safety? Patient Safety is a health care discipline that emerged with the evolving complexity in health care systems and the resulting rise of patient harm in health care facilities. It aims to prevent and reduce risks, errors and harm that occur to patients during provision of health care.
This document provides an overview of Inovio Pharmaceuticals and their DNA vaccine platform. It discusses their vaccine development process, clinical pipeline targeting diseases like cancer, HIV, influenza, and hepatitis C. It highlights positive interim clinical trial results and upcoming milestones. The document also introduces the management team and scientific advisors driving the company's work developing what they aim to be revolutionary DNA vaccines.
Oncoceutics leerink global healthcare 2015oncoceutics
- Oncoceutics has discovered a novel class of compounds called ONC201 that shows compelling efficacy against aggressive and refractory tumors in preclinical studies.
- Phase I/II clinical trials are underway at leading cancer centers to evaluate ONC201's safety and efficacy in hematological malignancies and solid tumors.
- ONC201 engages multiple critical cancer pathways without toxicity, demonstrating potential as a first-in-class therapeutic for treatment-resistant cancers.
This document provides a company presentation by Dan Peres, MD, Senior VP of Innovation at Immuron. It begins with a forward-looking statement noting that certain statements in the presentation are based on estimates and projections and are subject to risks. The presentation then discusses Immuron's oral immunotherapy approach, which aims to alter the systemic immune system using ingestible compounds to target the innate immune system of the gut and promote regulatory T cells to suppress inflammation. Key products in Immuron's pipeline include IMM-124E for fatty liver disease, diabetes, and Clostridium difficile, as well as IMM-529 specifically for Clostridium difficile. The presentation concludes with an overview of Immuron's corporate
Immuron Limited is a clinical-stage biopharmaceutical company targeting inflammatory and infectious diseases with oral immunotherapies. It has two lead clinical assets in Phase 2 development for fatty liver disease and C. difficile infection. It also has a registered and revenue-generating Travelan product targeting traveler's diarrhea. The company is listed on the NASDAQ and ASX exchanges and has an experienced management team supported by key opinion leaders. It is well positioned to address significant unmet needs in liver disease and infectious disease markets with blockbuster potential. Near-term milestones include interim data readouts from multiple Phase 2 NASH and pediatric NAFLD trials in 2017-2018.
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013Company Spotlight
This document summarizes information presented by Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, Inc. It discusses Inovio's DNA immunotherapy technology, clinical programs, partnerships, leadership, and upcoming value drivers. Key points include:
- Inovio is developing DNA-based immunotherapies delivered using electroporation for cancers and infectious diseases.
- Their lead program, VGX-3100 for HPV-related cancers, has shown strong T-cell responses and is in Phase II trials with efficacy data expected in mid-2014.
- Inovio has partnerships with Roche for prostate cancer and hepatitis B therapies and external funding to support several clinical programs.
The document describes a sepsis innovation portfolio comprised of therapeutics, diagnostics, devices, and digital health solutions to transform sepsis diagnosis, treatment, and monitoring. It summarizes several projects, including a portable monitoring system for early sepsis detection using a sensor ring, a rapid diagnostic panel to detect endothelial cell damage and blood biomarkers of sepsis, an ultrasound device to non-invasively monitor lung function and fluid status, a point-of-care diagnostic using whole blood redox measurements, an immunotherapy using interleukin-15 to boost the immune response, and a diagnostic to directly detect microbial DNA and identify antibiotic resistance within 3 hours. The portfolio aims to improve patient outcomes and reduce healthcare costs.
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Medpace
Given the accelerating pace of immuno-oncology clinical research, awareness of the specific challenges and considerations in designing and conducting successful trials for these new agents is critical.
This document summarizes the work of Dr. J. Joseph Kim and Inovio Pharmaceuticals to revolutionize vaccines. It discusses Inovio's DNA vaccine technology which uses plasmids and electroporation to efficiently stimulate the immune system. Key points include:
- DNA vaccines can provide universal and therapeutic immune responses against multiple strains of diseases like HPV, cancer, HIV, influenza.
- Clinical trials show DNA vaccines generate best-in-class T-cell and antibody responses.
- The company is developing vaccines for cancers, HPV, HIV, influenza, hepatitis through partnerships and clinical trials.
- A partnership with Roche will develop prostate cancer and hepatitis B vaccines.
This document summarizes Dr. J. Joseph Kim's presentation on revolutionizing vaccines through Inovio's DNA vaccine technology. Some key points:
- Inovio is developing DNA vaccines that use plasmids and electroporation to stimulate the immune system and generate antibody and T-cell immune responses.
- Their vaccines have shown best-in-class immune responses in clinical trials for HPV and HIV.
- Their lead vaccine, VGX-3100 for HPV-related cancers and diseases, is in Phase II trials with efficacy data expected in mid-2014.
- Inovio is targeting major markets for cancers and infectious diseases and collaborating with partners like Roche to develop and commercial
Cytori Therapeutics is presenting at the 26th Annual Roth Conference. They provide an overview of their adipose-derived cell therapy technology and development pipeline. Their focus is on cardiovascular disease and soft tissue injuries. Key highlights include their ongoing Phase II U.S. heart failure trial, a U.S. government contract for up to $106 million to develop treatment for thermal burns, and a pipeline supported by independent clinical studies of additional indications. They discuss their commercial model of selling proprietary cell therapy devices and single-use consumables, as well as progress on strategic partnerships.
GlobeImmune is a biotechnology company founded in 1995 by three University of Colorado faculty to commercialize their inventions from the lab. The company developed recombinant yeast-based immunotherapies and vaccines, with an initial focus on HIV. After hiring a professional CEO in 2002 and obtaining venture capital financing, the company shifted its focus to cancer immunotherapy. GlobeImmune has raised over $180 million in financing to date and completed multiple clinical trials. Its lead products are whole, heat-killed recombinant yeast immunotherapeutics for various cancer indications.
2. Overview: AVIcure BioScience, LLC.
• AVIcure develops, manufactures and markets patented medical devices for:
– Blood component pathogen reduction ( 10-6
sterilization )
– Immune System Stimulation
– Pulse Radio Frequency (Pain Relief)
• Founded in 2013
• Located in Bethlehem, PA
• Total employees: 8
• Capitalization:
– Funding from initial investors
– Private Placement
– Sale of Assets
– Corporate Sponsorship
2
2 Private and Confidential
3. Company Strengths
• Deep pipeline addresses high need market segments:
– Blood pathogen reduction
– Immune system stimulation
• Strong IP position
• A strong management team and advisers with scientific and business expertise to
execute company business plan
3
3 Private and Confidential
4. 4
The Blood Management Company
Confidential
AVIcure Focus
AVIcure designs, develops and
manufactures medical devices using
advanced ultraviolet light technology.
The devices, though different in
application, use ultraviolet light to
stimulate the immune system and
reduce blood borne pathogens providing
for both therapeutic and preventative
applications.
5. AVIcure Portfolio – focus on blood purification
5
5 Private and Confidential
Product Indication Research Preclinical Clinical Trials Marketed
Market
Opportunity
HemaSterilizer™
Blood Pathogen
Inactivation
$2.5 Billion (US)
and $7.5 Billion
(Global)
ImmunoModulator Chronic viral infections
$12.3 Billion (US;
for Hepatitis C and
influenza)
AVIcure™ Device
Chronic
temporomandibular joint
(TMJ) pain and anterior
knee pain
$300 Million
(Global)
6. 6
The HemaSterilizer™
HemaSterilizer (HS) technology provides a medical device
platform designed to inactivate pathogens in Red Blood
Cell (CRBC) concentrates intended for transfusion using UV
light technology.
Confidential
Pipeline Products - HemaSterilizer™
7. Market Need: Blood Safety
Viral disease transmission
• Improved but still present
– <than 1:1M transfusions for HIV, 1:250,000 for hepatitis C,
and 1:500Kfor hepatitis B
• Emerging viruses
– Ebola virus, West Nile virus, human herpes virus 8, and
several small DNA viruses (TTV, SEN-V)
• Microbial contamination
• Approved inactivation protocols lacking
– No completely reliable method for pathogen inactivation in
donated blood components and whole blood in US
• Potential safety and blood component recovery issues
– Immune reactions, reduced RBC recovery and survival
7
LACK OF ACCESS TO SAFE BLOOD WORLDWIDE
No completely reliable pathogen inactivation system available
7 Private and Confidential
8. The HemaSterilizer™ Concept
• Device exposes concentrated red blood
cells (CRBC) to an Ultraviolet C (UVC) light
source
• Designed for use in a blood bank
• Uses proprietary design to minimize
handling and achieve sterilization
acceptance
• Initial Phase 1 bench testing
8
8 Private and Confidential
10. Why the HemaSterilizer™ System Will Perform
• UVC was shown to reduce the levels of
purposely contaminated red cells with no
adverse effect.
• Initial inactivation goal is 5 Log with <1%
hemolysis.
• AVIcure’s Bench laboratory test results:
– RBC Concentration inactivation test
achieved 6 Log reduction with some
induced hemolysis.
10
10 Private and Confidential
11. Comparison: HemaSterilizer vs.
Other RBC Sterilization Methods
• Uses known principles to
achieve inactivation without
drugs/chemicals
• Inactivates all known
viruses
• Excellent recovery and
survival of RBCs
• Relative ease of use
• Require potentially toxic
chemicals (PEN110,
Dimethylmethylene blue,
Riboflavin, Psoralen, S-303,
others)
• Immunogenicity (S-303)
• Lack of efficacy against
some pathogens (PEN110
against TTV and SEAN-V)
• Reduced RBC recovery and
survival
• Complicated use
11
HemaSterilizer “Other” Systems
11 Private and Confidential
12. Status & Next Steps
• Phase 1 prototype model available for testing
• Preclinical Studies
– Demonstrate inactivation of pathogenic (model) viruses >5 logs with
<1% hemolysis
– RBC recovery and survival after 42 days storage
– <1% hemolysis after 42 day standard storage
– Assess immunogenicity
• Clinical Studies with Sponsorship
– Phase I, II and III human clinical studies designed to demonstrate
safety
12
12 Private and Confidential
13. 13
The ImmunoModulator™
First-in-class patented ImmunoModulator (IM) technology
designed to address life threatening RNA viruses,
“autoimmune” diseases (e.g. Psoriasis) and potentially
other illnesses by treating whole blood with ultraviolet
(UV) photopheresis
Confidential
Pipeline Products - ImmunoModulator™
14. Market Need: Hard-to-Treat Diseases
• Hepatitis C
– 3.2 million patients in U.S.
– 170 million patients worldwide
• Human HIV
– 1.1 million patients in U.S.
– 33.4 million patients worldwide
• H1N1/Influenza
– < 200,000 hospitalized in U.S. annually
– 3-5 million severe cases reported worldwide
• Psoriasis
– 4.5-7 million patients in U.S.
– 125 million patients worldwide
• MAP (Mycobacterium Avium Paratuberculosis)
– Role in Crohn disease (CD), Type 1 diabetes mellitus (T1DM) and Multiple Sclerosis
(MS)- first case of MAP eradication with cure of CD used UVBI
– Role in complex Regional Pain Syndrome (CRPS)
14
TARGETS BLOOD-BORNE DISEASES SUCH AS HEPATITIS C, HIV/AIDS, H1N1
14 Private and Confidential
15. The ImmunoModulator™ Concept
• IM device exposes the patient’s whole blood to an
Ultraviolet (UV) light source
– Treatment process involves removing a small amount
of blood (3-4%) from the patient, then exposing the
blood to a precise amount of UV energy for a precise
amount of time
– During treatment, UV exposed cells activate the
immune system resulting in immune modulation.
– After exposure, the blood is returned to the patient
through the same portal it was drawn from
– The treated blood stimulates immune system cells.
15
15 Private and Confidential
16. The ImmunoModulator™ System
• ImmunoModulator (IM) technology developed to utilize broad band ultraviolet light
(200nm-400nm).
• Unlike conventional drug therapies that appear to be limited by a patient's ethnicity
and viral genotype, the IM is uniquely safe and highly effective for all ethnic groups
and viral genotypes
• Demonstrates favorable safety and efficacy profile of standard HCV and HIV
treatments
• No recorded severe adverse event (300 Procedures)
• Potentially viable alternative or adjunctive treatment for a wide range of pathogens,
“autoimmune” diseases and certain cancers
16
FIRST-IN-CLASS DEVICE
16 Private and Confidential
18. Clinical Studies/Data
Data to date:
• Hepatitis C
– Granted two IDE approvals by FDA for human non-responder trials
– Safety and efficacy data from first trial sufficient to initiate second
• Human HIV
– Early results suggest reduction in viral load and stable CD4 counts
• H1N1/Influenza A
– Pre-clinical research conducted at the request of the U.S. Food and
Drug Administration
– Initial results suggests device inhibited viruses and reduced
inflammation in the lungs
• Psoriasis
– Two HCV study patients had prior histories of moderate and severe
psoriasis. Both patients experienced long term reduced symptoms.
18
STUDIES PREVIOUSLY CONDUCTED IN MULTIPLE INDICATIONS
18 Private and Confidential
19. Future
• Influenza Study
• Mycobacterium Avian Complex (MAC) Study
19
19 Private and Confidential
Mechanism of Action
• Viral Diseases
• Bacterial Diseases
• Immune Deficiencies such as Crohn's Disease and Psoriasis
20. 20
• Todd Kuenstner, CEO and Chief Medical Officer. Dr Kuenstner is a pathologist who is currently the
Medical Director or Clinical Laboratories at the Charleston Area Medical Center in Charleston, West
Virginia. Previously, he was the Director of Clinical Chemistry for Aurora Health Care in southeastern
Wisconsin. He received his pathology training at the Walter Reed Army Medical Center in Washington,
D.C.. In addition to being a practicing physician Dr. Kuenstner is an inventor and holds several patents
pertaining to non-invasive hemoglobin and carboxy-hemoglobin testing.
• Frank R. Bonanni, President. BS Chemistry from Fairleigh Dickinson University. Experience includes
Corporate Vice President International Development at CRBard, Inc., Vice President Business
Development and CEO at North American Sterilization and Packaging.
• Kenneth R. Cohen, Esq. General Counsel. Graduated from Rutgers University and New York University
School of Law. Kenneth R. Cohen is a member of the law firm of Davidson, Sochor, Ragsdale & Cohen,
LLC. His practice includes business law, estate planning, and administration, asset protection and elder
law with special emphasis in taxation.
• Dennis A. Losco, Vice President of Operations. Graduated from Fairleigh Dickinson with a BS degree in
Mechanical Engineering in 1967. Joining Superior Quartz Products in 1969 as head of their engineering
department, he has been designing medium pressure lamps for forty five years. Inventor of a platform
based multiple foil high current seal for medium pressure lamps. He has served as President of Superior
Quartz Products since 1995.
Confidential
Officers
21. 21
• Dennis J. Losco, Controller. Graduated from Farleigh Dickinson in 1991 with a degree in Business Management.
Joined Superior Quartz Products, Inc in 1991 and has held several positions of increasing responsibility, including
Director of Sales and Corporate Treasurer. Assumed responsibility of controller at AVIcure in 2013.
• Jeffry W. Losco, Vice President of Mechanical Engineering. Lafayette College - 1993 - BS Mechanical Engineering.
Superior Quartz Products - 1988-Present - VP and Director of Engineering. Co-Inventor of Patent for Cup Seal
Design for Foil-less high current medium pressure lamp. Co-Inventor of Patent for Discharge Lamp with Self
Supporting Electrode Structures. Avicure Bioscience - 2013-Present - Vice President of Mechanical Engineering
and Chairman of Science Committee.
• Joseph W Losco, Vice President of Electrical Engineering. Graduated from Bucknell University, Cum Laude, with a
degree in Electrical Engineering in 2004. After graduation began working at Superior Quartz Products, Inc. as the
Director of Electrical Engineering. In 2013, he joined AVIcure as Vice President of Electrical Engineering.
• Roger R. Marvinney Sr., Vice President of Marketing. Over 20 years of building sales and marketing organizations
in Silicon Valley high technology companies with an initial background in corporate finance at a global NY
financial institution. Mr. Marvinney has established a very successful record in venture funded start-ups and is
responsible for developing North American Sterilization and Packaging's core business as well as building the new
medical device technology incubator business for North American Sterilization and Packaging.
• Thomas Petrie, Vice President of Technology. The inventor of the ImmunoModulator and HemaSterilizer
technologies. He has spent his entire career in the medical device industry where he has held senior management
positions at Becton Dickenson, Data Scope, and Personal Diagnostics. His involvement with UVBI technologies
exceeds 20 years.
Confidential
Officers
22. 22
• Preston A. Marx, PhD. He is a Professor of Tropical Medicine at the Tulane School of Public
Health and Tropical Medicine, the Tulane National Primate Research Center, and a member of the
AIDS Research Advisory Committee, National Health Institute.
• Dr. Konstantin “Gus” Kousoulas, PhD. He is the Director of Biotechnology and Molecular
Medicine (BIOMMED) at Louisiana State University, School of Veterinary Medicine and the LSU-
Tulane NIH COBRE Center for Experimental Infectious Disease Research.
• Noshir Mehta Professor and Chair. Asst Dean at Tufts Dental School; Assoc. Dean International
Relations; Chair. General Dentistry and Director Craniofacial Pain center at Tufts University School
of Dental Medicine
• Stuart Weg, MD. Stuart Weg, MD has 30 years' experience in anesthesiology and pain
management. His practice evolved from mainstream pain management to use alternative
therapies to treat many chronic diseases and other types of imbalances that have been difficult to
treat effectively with conventional medicine. Dr. Weg received his medical doctorate from the
University of Monterrey in Mexico and completed an internship at Memorial Sloan Kettering
Cancer Center as well as an anesthesia residency at Beth Israel Hospital Medical Center with the
New York Mount Sinai Medical School. He also completed a preceptorship in Invasive Pain
Management under the Chair of Anesthesiology at Texas Tech University.
Confidential
Advisers